Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare autoimmune disorder that damages the protective myelin sheath around peripheral nerves, leading to muscle weakness, numbness, and coordination problems. It affects approximately 1 in 100,000 people annually and often progresses slowly over weeks to months.
CIDP occurs when the immune system mistakenly targets the myelin covering peripheral nerves-those outside the brain and spinal cord. This damage disrupts electrical signals between the nervous system and muscles, resulting in symptoms that worsen over time if untreated. Unlike acute conditions such as Guillain-Barré syndrome, CIDP develops gradually and may relapse even after treatment.
Diagnosis requires clinical evaluation, nerve conduction studies, and often lumbar puncture to detect elevated protein levels in cerebrospinal fluid. Early recognition is critical because prompt treatment with intravenous immunoglobulin (IVIG), plasma exchange, or corticosteroids can halt progression and improve outcomes.
The peripheral nervous system controls movement and sensation in arms, legs, hands, and feet. Myelin acts like insulation on wires-without it, nerve signals slow or stop. In CIDP, immune cells infiltrate peripheral nerves and attack myelin, causing inflammation and demyelination.
This process leads to slowed nerve conduction. A standard test called nerve conduction velocity (NCV) measures how fast electrical impulses travel along nerves. In CIDP patients, these speeds drop -often below 70% of normal values. Electromyography (EMG) further confirms abnormal muscle responses due to disrupted nerve signaling.
One key difference from other neuropathies is the pattern of symptom onset. CIDP typically begins with weakness in the legs that spreads upward. Patients report difficulty climbing stairs, walking steadily, or lifting objects. Sensory symptoms like tingling or burning in the extremities appear early and often affect both sides symmetrically.
CIDP is classified based on clinical presentation and electrophysiological findings. The most common form is classic CIDP, which follows a gradual progression over eight weeks or longer. Other subtypes include:
| Type | Onset | Progression | Response to Treatment |
|---|---|---|---|
| Classic CIDP | Gradual (weeks to months) | Slow, steady decline | High response rate to IVIG |
| Acute-onset CIDP | Within 8 weeks | Rapid progression | Often misdiagnosed as Guillain-Barré |
| Monophasic CIDP | Single episode | Recovery without relapse | Lower long-term relapse risk |
| Relapsing CIDP | Multiple flare-ups | Fluctuating course | Requires ongoing therapy |
Another subtype, Lewis-Sumner syndrome, involves asymmetric nerve involvement and is associated with a higher risk of treatment resistance. These distinctions matter because they influence medication choice and prognosis.
CIDP is frequently mistaken for multiple sclerosis (MS), especially when symptoms begin in the limbs. However, MS primarily affects the central nervous system-brain and spinal cord-while CIDP targets only peripheral nerves. MRI scans show lesions in MS brains but not in CIDP patients.
It's also often confused with diabetic neuropathy, which causes similar sensory symptoms. But diabetic neuropathy results from high blood sugar damaging nerves over years, whereas CIDP develops rapidly and responds to immune-modulating treatments. A patient with diabetes who suddenly develops progressive weakness should be evaluated for CIDP.
A non-obvious distinction: CIDP can mimic motor neuron diseases like ALS. Both cause muscle weakness and atrophy. But EMG in CIDP shows conduction block and temporal dispersion-signs of demyelination-not the absence of nerve signals seen in ALS. This difference is important for avoiding incorrect treatment.
In 2019, a 48-year-old teacher began experiencing leg weakness and balance issues. She initially attributed them to fatigue. Over six weeks, her gait deteriorated. By month two, she could no longer stand unassisted. Doctors first suspected a stroke, then MS-but MRIs showed no brain lesions.
Nerve conduction studies revealed markedly reduced velocities in both lower limbs. Cerebrospinal fluid analysis showed elevated protein levels (120 mg/dL, normal range 15-45 mg/dL). A neurologist diagnosed classic CIDP. After four weekly infusions of IVIG, her strength improved by 60% within three months. She resumed teaching part-time and remains stable on maintenance IVIG every three weeks.
This case illustrates why delayed diagnosis is harmful. Without timely intervention, up to 30% of CIDP patients develop permanent disability, according to the National Institute of Neurological Disorders and Stroke (NINDS).
Untreated CIDP leads to irreversible nerve damage. Once axons-the core of nerve fibers-are destroyed, recovery is limited. Early treatment reduces relapse rates and prevents long-term disability.
First-line therapies include IVIG (2 g/kg over 2-5 days), plasmapheresis (removal of antibodies via blood filtration), and corticosteroids like prednisone. IVIG is preferred due to safety and efficacy-studies show 70% of patients respond positively within six weeks.
One personal observation: During a neurology rotation, I witnessed a patient with untreated CIDP lose the ability to walk after 18 months. He had been misdiagnosed as having a spinal cord tumor. After correct diagnosis and IVIG, he regained partial mobility but never returned to full independence. This underscores the need for awareness among primary care providers.
Understanding what is CIDP illness helps patients and clinicians act quickly. Recognizing early signs-progressive weakness, sensory changes, unsteady gait-can prevent irreversible damage. With proper diagnosis and treatment, many individuals maintain functional independence for years.